COVAX reaches over 100 economies, 42 days after the first international delivery
Geneva/New York/Oslo, 8 April 2021 – More than one hundred economies have received life-saving COVID-19 vaccines from COVAX, the global mechanism for equitable access to COVID-19 vaccines. The milestone comes 42 days after the first COVAX doses were shipped and delivered internationally, to Ghana on February 24th.
COVAX has now delivered more than 38 million doses across six continents, supplied by three manufacturers, AstraZeneca, Pfizer-BioNTech and the Serum Institute of India (SII). Of the over 100 economies reached, 61 are among the 92 lower-income economies receiving vaccines funded through the Gavi COVAX Advance Market Commitment (AMC).
Despite reduced supply availability in March and April – the result of vaccine manufacturers scaling and optimising their production processes in the early phase of the rollout, as well as increased demand for COVID-19 vaccines in India – COVAX expects to deliver doses to all participating economies that have requested vaccines in the first half of the year.
“In under four months since the very first mass vaccination outside a clinical setting anywhere in the world, it is tremendously gratifying that the roll-out of COVAX doses has already reached one hundred countries,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “COVAX may be on track to deliver to all participating economies in the first half of the year yet we still face a daunting challenge as we seek to end the acute stage of the pandemic: we will only be safe when everybody is safe and our efforts to rapidly accelerate the volume of doses depend on the continued support of governments and vaccine manufacturers. As we continue with the largest and most rapid global vaccine rollout in history, this is no time for complacency.”
“COVAX has given the world the best way to ensure the fastest, most equitable rollout of safe and effective vaccines to all at-risk people in every country on the planet,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “If we are going to realize this great opportunity, countries, producers and the international system must come together to prioritize vaccine supply through COVAX. Our collective future, literally, depends on it.”
“This is a significant milestone in the fight against COVID-19. Faced with the rapid spread of COVID-19 variants, global access to vaccines is fundamentally important to reduce the prevalence of the disease, slow down viral mutation, and hasten the end of the pandemic,” said Dr Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI). “The extraordinary scientific achievements of the last year must now be matched by an unprecedented effort to protect the most vulnerable, so the global community must remain firmly focused on reducing the equity gap in COVID-19 vaccine distribution.”
“In just a month and a half, the ambition of granting countries access to COVID vaccines is becoming a reality, thanks to the outstanding work of our partners in the COVAX Facility,” said Henrietta Fore, UNICEF Executive Director. “However, this is no time to celebrate; it is time to accelerate. With variants emerging all over the world, we need to speed up global rollout. To do this, we need governments, along with other partners, to take necessary steps to increase supply, including by simplifying barriers to intellectual property rights, eliminating direct and indirect measures that restrict exports of COVID-19 vaccines, and donating excess vaccine doses as quickly as possible.”
According to its latest supply forecast, COVAX expects to deliver at least 2 billion doses of vaccines in 2021. In order to reach this goal, the COVAX Facility will continue to diversify its portfolio further, and will announce new agreements with vaccine manufacturers in due course.
Furthermore, in March it was announced that the United States government will host the launch event for the 2021 Gavi COVAX AMC Invest Opportunity to catalyze further commitment and support for accelerated access to vaccines for AMC-supported economies. An additional US$2 billion is required in 2021 to finance and secure up to a total of 1.8 billion donor-funded doses of vaccines. COVAX is also working to secure additional sourcing of vaccines in the form of dose-sharing from higher-income countries. ###
